Ajay Sasidharan

MD DNB FRCR
Radiation Oncology, Amrita Institute of Medical Sciences

[Adela @adelapoite]

Long-Term Analysis of NRG Oncology RTOG 0539: A Phase II Trial of Observation for Low-Risk Meningioma and Radiotherapy for Intermediate- and High-Risk Meningioma | Journal of Clinical Oncology https://t.co/cznUV0d54n

[Vedang Murthy @VedangMurthy]

Very proud of my whole team esp @indranilsays for brilliantly presenting the 1y AE data of the largest RCT in HR and N+ CaP.
SBRT is safe! Gr 3 AE very low.
More to follow....

[Sushil @Sushilberiwal]

fast forward 10 years data showing non inferiority of 26 in 5 to 49 in 15 for early stage breast cancer #estro2026

[Bobby Koneru, MD @KoneruMd]

We just found out our work will be presented at the ASTRO 2026 Plenary Session.

Not a poster. Not a breakout. The Plenary.

Low-dose radiotherapy for knee osteoarthritis with sustained clinical benefit,

MRI-confirmed outcomes, 13-year randomized data.

Stay tuned. @ASTRO_org

[Ajay Sasidharan @dr_ajays]

@jaydetsky @Suman_radonc Congratulations on the presentation Suman! @Suman_radonc

[radoncreview_org @radoncreview]

Our “Best of” #ESTRO26 outline is now live! 🚀

What key studies are we missing?

Drop any important trials, abstracts, or presentations we should add 👇

https://t.co/MyeQVhxxSk

#RadOnc #ESTRO26 #ESTRO2026

[Joshua D. Palmer, MD @joshuapalmermd]

@_joesia @cristian_udo @dr_ajays @DineshMakuny @ArchyaDasgupta We also have a phase 3 in the ALLIANCE studying this in the us, and a cog trial for pediatrics with a similar design

[Ajay Sasidharan @dr_ajays]

Hypofractionation in Glioblastoma - Time to look beyond Stupp Protocol in younger and fit patients? Promising phase 2 trials from AIIMS. @_joesia @DineshMakuny @ArchyaDasgupta

[Ajay Sasidharan @dr_ajays]

@_joesia @PeterMacRadOnc Which patients are selected for preop SRS?

[Ajay Sasidharan @dr_ajays]

@bhash Felt bad not just for myself, but for others waiting there realising they are not getting the service they were promised.

[Ajay Sasidharan @dr_ajays]

@bhash Ola scooter brokedown. Took to service centre alloted through customer service and app, after paying pickup-auto to take my scooter. Reaching there found out that they are not taking in any service and about to close permanently (Ola centre in North Paravur, Kochi). Bad service!

[Rohit Malde @roxboxfix]

FAST forward Boost Trial

Trial Groups (Randomized 1:1:1)

Control: 48 Gy in 15 # (3 weeks).
Test 1: 31 Gy in 5 fractions (1 week).
Test 2: 30 Gy in 5 fractions (1 week).

Aim= Is 1-week SIB radiotherapy non-inferior to 3-week SIB in terms of 5-year local relapse

[Ajay Sasidharan @dr_ajays]

Sharing our publication on Adjuvant Chemoradiation in Endometrial Cancer.

https://t.co/JUUh36Xemn

- 40-50% of p53 mutated patients recurred within 5 years.

- Ongoing RAINBOW RED trial is testing maintenance Olaparib in p53 mutated.

[TMC Radiation Oncology @RadOncTMC]

𝑵𝒖𝒂𝒏𝒄𝒆𝒔 𝒐𝒇 𝑷𝒓𝒐𝒕𝒐𝒏 𝑩𝒆𝒂𝒎 𝑻𝒉𝒆𝒓𝒂𝒑𝒚: 𝑭𝒓𝒐𝒎 𝑪𝒐𝒎𝒎𝒊𝒔𝒔𝒊𝒐𝒏𝒊𝒏𝒈 𝒕𝒐 𝑪𝒍𝒊𝒏𝒊𝒄𝒔

XXII @TataMemorial Annual Radiotherapy Practicum
&
1st TMC - IBA Proton Therapy Practicum

🗓 12-13 September 2025
📍@ACTREC_TMC

🔗 Register https://t.co/RraUjXdEvk

[Rohit Malde @roxboxfix]

Prospective Largest Study for SIB
N=74 (FAST); N=280 (FAST-F)
SIB Dose=33 Gy(FAST);32 Gy (Fast-F)
Electrons÷207; Photons (147)

SIB showed worsening Cosmesis over time

[Sushil @Sushilberiwal]

Finally one positive data on breast cancer for oligoprogression. Focused only on HR positive breast cancer unlike previous studies with goal to continue same systemic treatment #bcsm

[Priyamvada Maitre @docpriyamvada]

🚨 POLCA-GB RCT 🇮🇳 sets new SOC for GB cancer, NACRT improves OS over NACT! #ASCO25
Huge congratulations @ReenaEngineer Ma'am!!! Inspiring us to explore new indications, not giving up despite all challenges 💪🏼💪🏼🏆🏆

[PDBrown @PDBrownOnc]

🚨Update Randomized Trial: Significantly Better KPS & Cognitive Function with SRS compared to HA-WBRT for 5-20 brain mets 🚨🚨🚨

[Felipe Couñago PhD @fcounago]

📢 #ASCO25: In pts w/ 5–20 brain mets, SRS/SRT led to fewer symptoms & less functional interference vs HA-WBRT, w/ similar OS (~8.4 mo).
🔬 Phase 3 RCT (n=196)
💡 SRS/SRT = new SoC for brain mets >4?

https://t.co/LRbke5g4js

#RadOnc #NeuroOnc #SRS #WBRT #BrainMets

[Tejaswi Kanala MD @TSKanala]

Dr @ReenaEngineer from @RadOncTMC presents results from Ph3 randomised POLCA-GB trial for LA Gall Bladder Ca #ASCO25

Addition of NACRT to NACT shows
✅Better response to Neoadjuvant Rx
✅Higher R0 resection rates
✅Higher EFS (4.9 Vs 10.6 mos)
✅Higher OS (10.1 Vs 21.8 mos)